Keytruda

A Hit and a Miss for Merck’s Keytruda
A Hit and a Miss for Merck’s Keytruda
BioSpace
Merck
Keytruda
prostate cancer
biliary tract cancer
Flag link:
Immuno-oncology goes subcutaneous
Immuno-oncology goes subcutaneous
EP Vantage
immuno-oncology
oncology
subcutaneous drug delivery
Keytruda
Merck
Tecentriq
Roche
Flag link:
Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Chasing Roche, Merck talks up subcutaneous Keytruda ahead of phase 3 data drop
Fierce Pharma
Merck
Keytruda
Roche
cancer
oncology
Flag link:
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop
Fierce Biotech
BioXcel Therapeutics
clinical trials
Keytruda
BXCL701
prostate cancer
Flag link:
Merck Highlights Growth Strategy at J.P. Morgan
Merck Highlights Growth Strategy at J.P. Morgan
BioSpace
Merck
JPMHC 2023
Keytruda
vaccines
M&A
Flag link:
OncoC4 doses first participant in ovarian cancer therapy trial
OncoC4 doses first participant in ovarian cancer therapy trial
Clinical Trials Arena
OncoC4
clinical trials
ONC-392
Merck
Keytruda
ovarian cancer
platinum-resistant ovarian cancer
Flag link:
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Moderna, Merck & Co. mRNA cancer vaccine slashes melanoma recurrence in Keytruda combo trial
Fierce Biotech
Merck
Moderna Therapeutics
MRNA
cancer immunotherapy
Keytruda
melanoma
Flag link:
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
Yahoo/Reuters
Mirati Therapeutics
adagrasib
Merck
Keytruda
metastatic lung cancer
lung cancer
Flag link:
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
GSK unveils Keytruda head-to-head data in lung cancer—and they look good at first glance
Fierce Pharma
GSK
Merck
Jemperli
Keytruda
clinical trials
non-small cell lung cancer
Flag link:
Merck scores another win for Keytruda, this time in HER2-negative cancer
Merck scores another win for Keytruda, this time in HER2-negative cancer
Endpoints
Merck
Keytruda
clinical trials
adenocarcinoma
Flag link:
Is Merck Too Dependent on Keytruda?
Is Merck Too Dependent on Keytruda?
Motley Fool
Merck
Keytruda
Flag link:
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Catching up with Keytruda, Regeneron scores frontline NSCLC approval for Libtayo/chemo combo
Endpoints
Regeneron
Libtayo
non-small cell lung cancer
Keytruda
Merck
Flag link:
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Gilead, Arcus slim phase 3 TIGIT trial to take on king Keytruda
Fierce Biotech
Gilead Sciences
ARCUS
clinical trials
Merck
Keytruda
domvanalimab
zimberelimab
non-small cell lung cancer
Flag link:
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?
Endpoints
Bristol Myers Squibb
Opdivo
melanoma
Merck
Keytruda
Flag link:
Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda
Kineta, Merck Strike Deal to Pair Anti-VISTA Antibody with Keytruda
BioSpace
Kineta
Merck
Keytruda
anti-VISTA
monoclonal antibodies
solid tumors
Flag link:
OncoSec sheds 45% of staff to fund IL-12 drug through Keytruda combo trial
OncoSec sheds 45% of staff to fund IL-12 drug through Keytruda combo trial
Fierce Biotech
OncoSec Medical
melanoma
clinical trials
Keytruda
layoffs
Tavo
Flag link:
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Fierce Pharma
Merck
Keytruda
cancer
oncology
ESMO
Flag link:
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
Flag link:
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Flag link:
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
Fierce Pharma
Merck
Keytruda
head and neck cancer
ESMO
Flag link:

Pages